Century Therapeutics to Present CNTY-813 Data at Upcoming Scientific Congresses
Century Therapeutics (NASDAQ:IPSC) announced that its abstracts were accepted for oral presentations of the CNTY-813 therapy program at two upcoming scientific congresses in September and October 2026. The company is targeting an IND submission by Q4 2026, with preclinical data showing durable glucose control without immunosuppression.
Topics: Century Therapeutics CNTY-813 scientific presentations type 1 diabetes therapy